Long-term efficacy of pregabalin in generalized anxiety disorder
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
A multicenter, randomized, placebo-controlled, double-blind study was conducted to evaluate the efficacy of pregabalin in preventing relapse of generalized anxiety disorder (GAD) after response to short-term treatment. Outpatients (n=624) with GAD for > or =1 year received open-label pregabalin (450 mg/day) for 8 weeks and, if a clinical response was observed, were randomized to receive either pregabalin (450 mg/day; n=168) or placebo (n=170) for 24 weeks. The primary efficacy parameter was time to relapse. Among responders to open-label acute treatment with pregabalin, time to relapse of GAD was significantly longer for patients treated with pregabalin compared with placebo (P<0.0001). Fifty per cent of the placebo group had relapsed by day 23, and at study endpoint, 65% had relapsed. In the pregabalin group, only 42% had relapsed by study end. Total attrition during double-blind treatment was somewhat higher on pregabalin compared with placebo (21.4 vs. 15.3%); attrition owing to adverse events (AEs) was also somewhat higher on pregabalin (6.0 vs. 2.4%). AEs were relatively low in the double-blind phase; only three AEs occurred with an incidence of more than 5% on pregabalin and placebo, respectively: infection (14.9 vs. 11.2%), headache (10.1 vs. 11.2%), and somnolence (6.0 vs. 0%). No safety concerns were identified with long-term treatment. The study indicates that pregabalin is an effective treatment for the prevention of relapse in patients with GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695 · cited 2×
“Depression is the most common comorbid condition with GAD (Carter et al., 2001; Kessler et al., 2002; Wang et al., 2005); the sustained improvements in depressive symptoms observed in our study suggest that pregabalin has the potential to improve such comorbid symptoms, but further research in…”
BackgroundSize and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967 · cited 2×
“Although a number of factors, including high levels of comorbidity (Brown and Barlow, 1992; Noyes et al., 1992; Brawman-Mintzer et al., 1993; Wittchen et al., 1994; Judd et al., 1998), contribute to this overall picture of disability, a diagnosis of GAD has itself been found to independently increase the risk of disab…”
BackgroundBruce, S. E., Yonkers, K. A., Otto, M. W., Eisen, J. L., Weisberg, R. B., Pagano, M., Shea, M. T., & Keller, M. B. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1179 · Cited by 963 · cited 1×
“(Bruce et al., 2005).”
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332 · cited 2×
“To assess possible withdrawal symptoms during discontinuation of study medication, the 20-item, clinician-rated Physician Withdrawal Checklist (PWC; Rickels et al., 1990) was administered at termination of the doubleblind phase and at each of the two weekly visits during the discontinuation phase.”
MethodAssessing impairment in patients with panic disorder: the Sheehan Disability Scale
Leon, A. C., Shear, M. K., Portera, L., & Klerman, G. L. (1992) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00788510 · Cited by 319 · cited 10×
“In addition, 24 weeks of pregabalin treatment (after 8 weeks of open-label treatment) resulted in significant and sustained improvements compared with placebo in all secondary efficacy measures, including anxiety symptoms as reflected by the HAM-A total score; depression symptoms as reflected by the HAM-D score; and w…”
MethodInfluentialWang, P. S., Bohn, R. L., Glynn, R. J., Mogun, H., & Avorn, J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.892 · Cited by 312
Wittchen, H.-U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00002 · Cited by 299
Judd, L. L., Kessler, R. C., PauIus, M. P., Zeller, P. V., Wittchen, H. ‐., & Kunovac, J. L. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05960.x · Cited by 222 · cited 1×
“…of factors, including high levels of comorbidity (Brown and Barlow, 1992; Noyes et al., 1992; Brawman-Mintzer et al., 1993; Wittchen et al., 1994; Judd et al., 1998), contribute to this overall picture of disability, a diagnosis of GAD has itself been found to independently increase the risk of…”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Zaccara, G., Gangemi, P., Perucca, P., & Specchio, L. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02966.x · Cited by 216
“Excluded studies From 53 potentially eligible RCTs, 15 studies (Anon, 2005c,d; Arnold et al., 2007; De Haas et al., 2007; Houghton et al., 2007; Zesiewicz et al., 2007; Anon., 2008a,c; Crofford et al., 2008; Feltner et al., 2008; Anon., 2009c,d,f; Ferrara et al., 2009; Kasper et al., 2009) were excluded from our analy…”
BackgroundHernandez, A. R., Hernandez, C. M., Campos, K., Truckenbrod, L., Federico, Q., Moon, B., McQuail, J. A., Maurer, A. P., Bizon, J. L., & Burke, S. N. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00391 · Cited by 111
“Furthermore, therapeutics targeting GABAeric systems are among the most commonly prescribed treatment options for anxiety-related disorders (Nemeroff, 2003; Pillay and Stein, 2007; Feltner et al., 2008; Gauthier and Nuss, 2015).”
BackgroundComprehensive review of generalized anxiety disorder in primary care in Europe.
Parmentier, H., García-Campayo, J., & Prieto, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.770731 · Cited by 37
Metadata
- Authors
- Feltner, D., Wittchen, H.-U., Kavoussi, R., Brock, J., Baldinetti, F., & Pande, A. C.
- Venue
- International Clinical Psychopharmacology
- Published
- 2008-01
- Volume
- 23
- Issue
- 1
- Pages
- 18-28
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2047602052
- Cited by
- 129
- References
- 13
- FWCI
- 18.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term efficacy of pregabalin in generalized anxiety disorder. https://app.cochat.ai/papers/10.1097/yic.0b013e3282f0f0d7
- The paper
- Feltner, D., Wittchen, H.-U., Kavoussi, R., Brock, J., Baldinetti, F., & Pande, A. C. (2008). Long-term efficacy of pregabalin in generalized anxiety disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e3282f0f0d7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.